Profectus Bio wins $200K grant for HIV therapies
Baltimore, Md.-based Profectus BioSciences, a biotech developing new strategies to attack HIV, received a $200,000 small-business innovation grant from the National Institutes of Health to improve the effectiveness of anti-HIV antibodies. Last month, the company received a similar $300,000 grant (PDF link), just a few days after the company raised $3 million in a private placement.
Profectus, which was spun out of the Institute for Human Virology in 2005, has so far rased a total of… Continue Reading
Snowdon wins $500K grant for parasitic disease
Snowdon, a New Brunswick, N.J., drug developer, received a $500,000 grant from the New Jersey Commission on Science & Technology. The grant matches $500,000 the company raised in March from the Foundation Venture Capital Group.
Snowdon is developing new treatments against cancer, pain and infectious parasitic diseases.